AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

Settled to April 2036Wide moat

Gilead Sciences (GILD) — moat facet

Gilead's October 2025 settlements pushed Biktarvy's earliest US generic date to 1 April 2036, more than two years later than it had expected.

The most valuable thing Gilead did in 2025 was not a launch but a settlement. On 6 October 2025 it settled its patent litigation with Lupin, Cipla and Laurus Labs, and under the agreements "no generic entry is expected prior to April 1, 2036 in the United States" for Biktarvy1. Gilead said that was "more than two years later than our previous loss of exclusivity projection for Biktarvy (December 2033)"2.

Biktarvy sales by region, 2025 ($M)11,467United States1,676Europe1,190Rest of worldGilead Form 10-K FY2025; US generics not before 1 April 2036, EU patent 2033
More than two years of exclusivity added by settlement.

Two more years of a product that sold $14,334 million in 20253 is worth a great deal. The settlement turned an uncertain patent fight into a known date and gave the switching strategy more time to work.

The chief executive drew the conclusion himself, saying there was "no major loss of exclusivity expected until 2036"4. That is a strong claim for a company whose main product is half its revenue, and it is true in the narrow sense: the patent cliff is now ten years out.

The date is conditional. The settlements are "subject to standard acceleration provisions"5, meaning that if another generic maker gets in earlier, the settling companies can follow. And in February 2026 Gilead filed a new lawsuit against Cipla over a Descovy patent challenge6, a reminder that a settlement covers one product, not a generic maker.

The settlement mattered to the share price as well as to the accounts. Gilead's market value was $115.12 billion at the end of 2024 and $152.28 billion at the end of 20257, a rise of a third in the year the Biktarvy date moved out. Not all of that was the settlement, but a known date ten years away is worth more than an uncertain one eight years away.

The settlement is holding as long as no generic Biktarvy is launched or authorised in the United States. Any court ruling that clears a non-settling generic for launch before 2036 would bring the date forward for all of them.

Moat trajectory: Widening

Generic entry moved from a projected December 2033 to April 2036.

The number that tests this moat
Reported
Biktarvy US sales, full year
$11,467M (2025), 80% of Biktarvy and up from $10,855M in 2024

The revenue the 2036 settlement protects; it is also what Medicare reprices in 2028.

Source: Gilead Sciences Form 10-K, FY2025 ↗
⚠ Threats to the moat
⚠ THREAT 01
Standard Acceleration Provisions
The 2036 Biktarvy date is only as strong as Gilead's position against generic makers who did not settle.
References
  1. ReportedOn 6 October 2025 it settled its patent litigation with Lupin, Cipla and Laurus Labs, and under the agreements "no generic entry is expected prior to April 1, 2036 in the United States" for Biktarvy.
    Gilead Sciences Form 8-K of 6 October 2025 - settlement agreements with Lupin, Cipla and Laurus Labs; no generic entry of Biktarvy expected in the United States before 1 April 2036. — October 2025 · publ. 6 October 2025 · source ↗
  2. ReportedGilead said that was "more than two years later than our previous loss of exclusivity projection for Biktarvy (December 2033)".
    Gilead Sciences third-quarter 2025 results release, Form 8-K exhibit 99.1 - the Biktarvy settlements, the PEPFAR lenacapavir partnership and the chief executive's statement on exclusivity. — Q3 2025 · publ. 30 October 2025 · source ↗
  3. ReportedTwo more years of a product that sold $14,334 million in 2025 is worth a great deal.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  4. ReportedThe chief executive drew the conclusion himself, saying there was "no major loss of exclusivity expected until 2036".
    Gilead Sciences third-quarter 2025 results release, Form 8-K exhibit 99.1 - the Biktarvy settlements, the PEPFAR lenacapavir partnership and the chief executive's statement on exclusivity. — Q3 2025 · publ. 30 October 2025 · source ↗
  5. ReportedThe settlements are "subject to standard acceleration provisions", meaning that if another generic maker gets in earlier, the settling companies can follow.
    Gilead Sciences Form 8-K of 6 October 2025 - settlement agreements with Lupin, Cipla and Laurus Labs; no generic entry of Biktarvy expected in the United States before 1 April 2036. — October 2025 · publ. 6 October 2025 · source ↗
  6. ReportedAnd in February 2026 Gilead filed a new lawsuit against Cipla over a Descovy patent challenge, a reminder that a settlement covers one product, not a generic maker.
    Gilead Sciences Form 10-K for 2025 - patents, regulatory exclusivity, expiry dates and settlements with generic manufacturers. — FY2025 · publ. 24 February 2026 · source ↗
  7. Third-party estimateGilead's market value was $115.12 billion at the end of 2024 and $152.28 billion at the end of 2025, a rise of a third in the year the Biktarvy date moved out.
    stockanalysis.com, Gilead Sciences market-cap history: year-end values 145.83 (2015), 94.34, 93.58, 80.92, 82.21, 73.03, 91.08, 107.68, 100.94, 115.12, 152.28 (2025), $ billions; up 30.13% in one year. — 2015-2026 · publ. 2 October 2026 · source ↗
Sources
Generated October 4, 2026